CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 22 enrolled
Drug / intervention
BOTOX® Injection +1 moredrug
Likely dose
BOTOX® Injection 2mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05620316
NCT05620316N/ACompleted

Evaluation of the Efficacy of Low-Dose Botulinum Toxin Injection Into the Masseter Muscle for the Treatment of Nocturnal Bruxism: A Randomized Controlled Clinical Trial

Damascus University·interventional·Posted Nov 17, 2022·Updated Nov 17, 2022

In Brief

A clinical study evaluating BOTOX® Injection and Prick skin for Nocturnal Bruxism. Completed, enrolled 22 participants across 1 site.

Detailed Summary

Botulinum toxin (BOTOX®) injections into the masseter muscle are an effective treatment for nocturnal bruxism, with several trials using various dosages of botulinum toxin for this purpose. The aim was to evaluate the effectiveness of injecting 10MU of botulinum toxin A (BTXA) into the masseter muscle to reduce nocturnal bruxism, the sample will randomly divided into 2 groups. In the injection group, Patients will inject with 10 MU of botulinum toxin type A (BOTOX® - Allergan Inc. - Dublin - Ireland) per side at two sites into the masseter muscle bilaterally. In this Placebo group, patients will prick twice at the inferior prominent part of the masseter muscle observed using the stinger pen used in the blood glucose meter. The evaluation will make by Electromyography (EMG) analysis, Visual Analogue Scale (VAS) values.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesSyria
Collaborators--

Timeline

N/ACompletedFinished
20222023202420252026
First PostedNov 17, 2022
Enrollment StartMar 15, 2021
Primary CompletionSep 15, 2021
Study CompletionFeb 10, 2022
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 3.6 years ago

Interventions

BOTOX® Injectiondrug

100 MU of botulinum toxin type A (BOTOX® - Allergan Inc. - Dublin - Ireland) were diluted in 2ml of saline. Patients were injected with 10 MU of BTXA per side at two sites into the masseter muscle bilaterally. The first site was the inferior prominent part of the masseter muscle observed when the subject was asked to clench, and the other site was 5 mm below the first point

Prick skinother

patients were pricked twice at the inferior prominent part of the masseter muscle observed using the stinger pen used in the blood glucose meter; it is less painful and provides psychological benefits, instead of injecting the physiological saline into the muscle to avoid the severe pain without a benefit to the patient which would not conform to the ethical standards.